Table 2.

Effect of glibenclamide and MSLA on the FBS of alloxan-induced diabetic rats treated for 21 d.

		Mean fasting blood glocuse levels ± SE
Group	Treatment	Pre-diabetic	Day 0	Day 7	Day 14	Day 21
1.	Normal saline (10 mL/kg)	79.25 ± 2.86	79.50 ± 2.39	79.00 ± 2.73	78.00 ± 2.27	72.75 ± 4.02
2.	Diabetic control (150 mg/kg)	83.25 ± 4.17	134.50 ± 2.98#	134.50 ± 3.42#	136.00 ± 2.16#	139.75 ± 3.32#
3.	Glibenclamide (2 mg/kg)	80.16 ± 1.49	140.33 ± 1.33	123.16 ± 3.72	122.83 ± 2.83	113.83 ± 3.68
4.	MSLA (300 mg/kg)	82.00 ± 5.24	136.00 ± 3.31	127.66 ± 3.09	108.16 ± 5.47a	101.83 ± 4.33a

Data are mean ± SEM, n=24. One-way ANOVA+Tukey test against diabetic rats

^# P<0.0001 Diabetic control rats were compared with normal control rats.

^* P < 0.05,

^** P < 0.001 and

^*** P < 0.0001 Diabetic treated rats were compared with diabetic control rats.

^a P < 0.05,

^b P<0.01 and

^c P<0.0001 Diabetic treated rats with MSLA were compared with Diabetic treated rats with glinenclamide on corresponding day.